Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.